Case report of oxalate nephropathy in a patient with pancreatic metastases from renal carcinoma by Purshouse, K, Chamberlain, S, Soares, M, Tuthill, M, Protheroe, A, Mole, D

Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non‐muscle‐invasive disease by Doyle, E, Crew, J, Mostafid, H, Tuthill, M, Cerundolo, V, Gerristen, W, Protheroe, A

Bilateral testicular germ cell tumors: A case-series from a UK-based tertiary referral center over 19 years by Watson, R, Morgan, R, Joseph, J, Sivakumar, S, Verrill, C, Tuthill, M, Sullivan, M, Protheroe, A

Changing practice evaluation—stage 1 seminoma: outcomes with adjuvant treatment versus surveillance: risk factors for recurrence and optimizing follow-up protocols—experience from... by Tyrrell, H, Church, D, Joseph, J, Traill, Z, Sullivan, M, Tuthill, M, Verrill, C, Pintus, E, Dallas, N, Rogers, P, Redgwell, J, Protheroe, A

Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer by Purshouse, K, Schuh, A, Fairfax, B, Knight, S, Antoniou, P, Dreau, H, Popitsch, N, Gatter, K, Roberts, I, Browning, L, Traill, Z, Kerr, D, Verrill, C, Tuthill, M, Taylor, J, Protheroe, A

Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? by Cheung, VTF, Gupta, T, Olsson-Brown, A, Subramanian, S, Sasson, SC, Heseltine, J, Fryer, E, Collantes, E, Sacco, JJ, Pirmohamed, M, Simmons, A, Klenerman, P, Tuthill, M, Protheroe, AS, Chitnis, M, Fairfax, BP, Payne, MJ, Middleton, MR, Brain, O

Digital pathology transformation in a supraregional germ cell tumour network by Colling, R, Protheroe, A, Sullivan, M, Macpherson, R, Tuthill, M, Redgwell, J, Traill, Z, Molyneux, A, Johnson, E, Abdullah, N, Taibi, A, Mercer, N, Haynes, HR, Sackville, A, Craft, J, Reis, J, Rees, G, Soares, M, Roberts, ISD, Siiankoski, D, Hemsworth, H, Roskell, D, Roberts-Gant, S, White, K, Rittscher, J, Davies, J, Browning, L, Verrill, C

A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP) by Starkey, T, Ionescu, MC, Tilby, M, Little, M, Burke, E, Fittall, MW, Khan, S, Liu, JKH, Platt, JR, Mew, R, Tripathy, AR, Watts, I, Williams, ST, Appanna, N, Al-Hajji, Y, Barnard, M, Benny, L, Burnett, A, Bytyci, J, Cattell, EL, Cheng, V, Clark, JJ, Eastlake, L, Gerrand, K, Ghafoor, Q, Grumett, S, Harper-Wynne, C, Kahn, R, Lee, AJX, Lomas, O, Lydon, A, Mckenzie, H, Panneerselvam, H, Pascoe, JS, Patel, G, Patel, V, Potter, VA, Randle, A, Rigg, AS, Robinson, TM, Roylance, R, Roques, TW, Rozmanowski, S, Roux, RL, Shah, K, Sheehan, R, Sintler, M, Swarup, S, Taylor, H, Tillett, T, Tuthill, M, Williams, S, Ying, Y, Beggs, A, Iveson, T, Lee, SM, Middleton, G, Middleton, M, Protheroe, A, Fowler, T, Johnson, P, Lee, LYW